Humana Inc (HUM) Shares Bought by Rockefeller Financial Services Inc.

Rockefeller Financial Services Inc. grew its holdings in Humana Inc (NYSE:HUM) by 40.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,498 shares of the insurance provider’s stock after acquiring an additional 1,855 shares during the period. Rockefeller Financial Services Inc.’s holdings in Humana were worth $1,612,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Aperio Group LLC grew its position in Humana by 1.1% in the fourth quarter. Aperio Group LLC now owns 133,656 shares of the insurance provider’s stock worth $33,156,000 after acquiring an additional 1,439 shares in the last quarter. Telemus Capital LLC acquired a new stake in shares of Humana in the fourth quarter worth $2,191,000. Summit Securities Group LLC acquired a new stake in shares of Humana in the fourth quarter worth $546,000. Kovack Advisors Inc. acquired a new stake in shares of Humana in the fourth quarter worth $260,000. Finally, CIBC World Markets Inc. acquired a new stake in shares of Humana in the fourth quarter worth $12,431,000. 94.39% of the stock is owned by institutional investors.

In other news, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the sale, the vice president now owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the sale, the senior vice president now directly owns 11,704 shares in the company, valued at approximately $2,901,304.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,115 shares of company stock valued at $2,501,627. Corporate insiders own 0.80% of the company’s stock.

Humana Inc (NYSE:HUM) opened at $276.50 on Monday. Humana Inc has a one year low of $189.01 and a one year high of $293.35. The stock has a market cap of $39,500.82, a price-to-earnings ratio of 21.75, a PEG ratio of 1.70 and a beta of 0.93. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the prior year, the company posted $3.18 EPS. The business’s revenue was down 3.0% on a year-over-year basis. sell-side analysts forecast that Humana Inc will post 11.63 earnings per share for the current year.

Humana announced that its Board of Directors has approved a share repurchase program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to reacquire shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

HUM has been the subject of a number of analyst reports. Cowen restated a “buy” rating and issued a $285.00 price objective on shares of Humana in a research note on Wednesday, December 13th. Goldman Sachs Group initiated coverage on shares of Humana in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $305.00 price objective for the company. Jefferies Group upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 price objective for the company in a research note on Friday, January 12th. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $297.00 price objective for the company in a research note on Monday, January 15th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $230.00 price objective on shares of Humana in a research note on Tuesday, December 5th. Nine research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $262.74.

ILLEGAL ACTIVITY WARNING: “Humana Inc (HUM) Shares Bought by Rockefeller Financial Services Inc.” was published by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.thestockobserver.com/2018/02/05/humana-inc-hum-shares-bought-by-rockefeller-financial-services-inc.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply